Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 11:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Alprostadil Clear all
Completed Not applicable Interventional Results available

Modern Urodynamics System Efficacy (MUSE) Study

NCT05959655
View directory record Official record
Conditions
Urologic Diseases, Urodynamics
Interventions
Glean Urodynamics System
Device
Lead sponsor
Bright Uro
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Murrieta, California • Newport Beach, California • East Setauket, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 1 Interventional

MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3

NCT04059523
View directory record Official record
Conditions
Acne Vulgaris
Interventions
S6G5T-3, Retin-A® 0.1% Cream
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
9 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Austin, Texas • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Sep 7, 2026, 11:02 AM EDT
Terminated Phase 2 Interventional

Efficacy & Safety of Single Dose Alprostadil Cream (2 Concentrations Enhancer) to Vehicle in Men w/Erectile Dysfunction

NCT01810575
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
WC3036-11F/Alprostadil in Vehicle 2.5%, WC3036-12F/Alprostadil in Vehicle 0.5%, WC3036-13P/Vehicle Only 0.5%
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
40 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Purchase, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 1 Interventional

Lubiprostone Effects on Visceral Pain Sensitivity

NCT01166789
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2011 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Lubiprostone, Colonic Motility and Sensation

NCT00953043
View directory record Official record
Conditions
Healthy
Interventions
lubiprostone, Placebo, Bowel preparation
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 26, 2012 · Synced Sep 7, 2026, 11:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Motion Immune Magnetic Resonance Imaging (MRI)

NCT02302521
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Multiplex Sensitivity Encoding (MUSE)
Device
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 3 Interventional Results available

Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone

NCT00620061
View directory record Official record
Conditions
Opioid-Induced Bowel Dysfunction
Interventions
Lubiprostone 24
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
120
States / cities
Birmingham, Alabama • Hueytown, Alabama • Mobile, Alabama + 95 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2020 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Not applicable Interventional

Meditation Utilizing Signals From Electroencephalography in Chronic Pain (MUSE-PAIN) Study

NCT04944459
View directory record Official record
Conditions
Chronic Pain
Interventions
Muse-S headband; InteraXon Inc., RRID:SCR_014418
Device
Lead sponsor
Center For Interventional Pain and Spine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Santa Rosa, California • Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 4 Interventional Results available

Lubiprostone in Patients With Multiple Sclerosis Associated Constipation

NCT01236534
View directory record Official record
Conditions
Multiple Sclerosis, Constipation
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Misoprostol Ripening Efficacy With Dilapan

NCT03670836
View directory record Official record
Conditions
Labor Onset and Length Abnormalities, Induced; Birth
Interventions
Dilapan, Misoprostol
Device · Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
307 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
2
States / cities
New York, New York • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

Lubiprostone as a Modulator of Gut Microbial Translocation in HIV With Incomplete CD4 Recovery on Antiretroviral Therapy

NCT01839734
View directory record Official record
Conditions
HIV
Interventions
Lubiprostone
Drug
Lead sponsor
Ruth M. Rothstein CORE Center
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 7, 2026, 11:02 AM EDT
Terminated Not applicable Interventional Results available

Lubiprostone as a Treatment for Constipation in Parkinson's Disease

NCT00669461
View directory record Official record
Conditions
Constipation, Parkinson's Disease
Interventions
Lubiprostone
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
50 Years to 85 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)

NCT02628236
View directory record Official record
Conditions
Keratosis, Actinic
Interventions
Aminolevulinic Acid (ALA), BLU-U
Drug · Device
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Austin, Texas • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2017 · Synced Sep 7, 2026, 11:02 AM EDT
Recruiting No phase listed Observational

Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users

NCT06659029
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Anifrolumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
Female only
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Lubiprostone in Pediatric Patients With Constipation

NCT00452335
View directory record Official record
Conditions
Constipation
Interventions
Lubiprostone
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 4 Interventional Results available

Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation

NCT01460225
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
lubiprostone
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

Maximal Use Systemic Exposure (MUSE) Study of Levulan Kerastick

NCT02281136
View directory record Official record
Conditions
Keratosis, Actinic
Interventions
Aminolevulinic Acid (ALA), BLU-U
Drug · Device
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
San Diego, California • Carmel, Indiana • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Sep 7, 2026, 11:02 AM EDT
Recruiting Early Phase 1 Interventional

Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System

NCT05291507
View directory record Official record
Conditions
Breast Cancer
Interventions
Muse MRgFUS System
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Not applicable Interventional

Assessment of the Functional Significance of Accessory Pudendal Arteries

NCT00577876
View directory record Official record
Conditions
Prostate Cancer
Interventions
Trimix Injection with Doppler Ultrasound
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2011 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 2 Interventional

Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis

NCT02228850
View directory record Official record
Conditions
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions
Alprostadil, Placebo
Drug · Other
Lead sponsor
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Industry
Eligibility
18 Years to 79 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Encinitas, California • Ann Arbor, Michigan • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Sep 7, 2026, 11:02 AM EDT
Recruiting Phase 4 Interventional

Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users

NCT06594068
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Anifrolumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 7, 2026, 11:02 AM EDT
Withdrawn Phase 2 Interventional

Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure

NCT00598429
View directory record Official record
Conditions
Infant, Newborn, Respiratory Insufficiency, Pulmonary Hypertension, Respiratory Distress Syndrome, Newborn, Streptococcal Infections
Interventions
Inhaled Prostaglandin E1
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 7 Days
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
11
States / cities
Birmingham, Alabama • Palo Alto, California • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpill in Patients With Chronic Constipation

NCT01469819
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Lubiprostone
Drug
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Sep 7, 2026, 11:02 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome

NCT02544152
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Huntsville, Alabama • North Little Rock, Arkansas • Chula Vista, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Sep 7, 2026, 11:02 AM EDT